Study Shows Javelin Pharma's (JAV) DylojectTM is Well-Tolerated in High-Risk Patients
Tweet Send to a Friend
Javelin Pharmaceuticals, Inc. (Amex: JAV) today reported encouraging findings from a new Phase I pharmacokinetic and safety study of Dyloject ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
